{"id":172455,"date":"2025-11-18T03:25:10","date_gmt":"2025-11-18T08:25:10","guid":{"rendered":"https:\/\/44.250.171.167\/?p=172455"},"modified":"2025-11-18T03:25:10","modified_gmt":"2025-11-18T08:25:10","slug":"granules-india-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/granules-india-q2-fy26-earnings-results\/","title":{"rendered":"Granules India Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Granules India Ltd and its subsidiaries, specializing in Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages, posted impressive financial results for Q2FY26.<\/p>\n<h2>Financial Highlights:<\/h2>\n<ul>\n<li>Revenues increased 34.13% year-on-year to \u20b91,297 crore from \u20b9967 crore.<\/li>\n<li>Total expenses rose 33.02% to \u20b91,120 crore from \u20b9842 crore.<\/li>\n<li>Consolidated net <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/4a7c9901-4490-4f47-9ac5-9575f1b2f52b.pdf\" target=\"_blank\" rel=\"noopener\">profit<\/a> jumped 35.05% to \u20b9131 crore from \u20b997 crore.<\/li>\n<li>Earnings per share improved 34.16% to \u20b95.38 from \u20b94.01.<\/li>\n<\/ul>\n<p>The strong operational performance was driven by rising export demand, product diversification, and improved cost management.<\/p>\n<h2>Outlook:<\/h2>\n<p>Granules India is focused on expanding global market share, launching complex generics, and strengthening its manufacturing capabilities. Continued investment in research and development will support innovation and sustain future growth.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/granules\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-172456\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/G-6.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/G-6.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/G-6-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/G-6-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/G-6-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/G-6-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Granules India Ltd and its subsidiaries, specializing in Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages, posted impressive financial results for Q2FY26. Financial Highlights: Revenues increased 34.13% year-on-year to \u20b91,297 crore from \u20b9967 crore. Total expenses rose 33.02% to \u20b91,120 crore from \u20b9842 crore. Consolidated net profit jumped 35.05% to \u20b9131 crore [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":172456,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[11776],"class_list":["post-172455","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-active-pharmaceutical-ingredients"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/G-6.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":146247,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-granules-india-limited-for-q4-fy23\/","url_meta":{"origin":172455,"position":0},"title":"Earnings Summary Of Granules India Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 16, 2023","format":false,"excerpt":"Granules India Limited is a pharmaceutical manufacturing company based in India. The company is engaged in the production and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). With a strong focus on quality, innovation, and customer satisfaction, Granules India has established itself as a\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-2-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-2-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-2-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-2-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-2-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-2-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":141857,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-granules-india-limited-for-q3-fy23\/","url_meta":{"origin":172455,"position":1},"title":"Earnings Summary Of Granules India Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 15, 2023","format":false,"excerpt":"Granules India Limited (NSE: GRANULES) is a pharmaceutical manufacturing company based in Hyderabad, India. The company was founded in 1984 and has grown to become a leading producer of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, and other healthcare products. Revenue from Operations was \u20b91,146 Cr, up 15% year on year,\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-13.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-13.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-13.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-13.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-13.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-13.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177861,"url":"https:\/\/alphastreet.com\/india\/granules-india-q3-fy26-earnings-results\/","url_meta":{"origin":172455,"position":2},"title":"Granules India Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 27, 2026","format":false,"excerpt":"Executive Summary Granules India Ltd reported Q3FY26 revenues of \u20b91,388 crore, up 21.97% YoY, with consolidated net profit rising 27.12% to \u20b9150 crore. Total expenses increased 19.37% YoY to \u20b91,183 crore, reflecting efficient cost management amid strong revenue growth. Revenue & Growth Revenues grew to \u20b91,388.00 crore in Q3FY26 from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166823,"url":"https:\/\/alphastreet.com\/india\/granules-india-ltd-q3fy25-6-fall-in-profits\/","url_meta":{"origin":172455,"position":3},"title":"Granules India Ltd Q3FY25; 6% fall in Profits","author":"Divyansh_Kasana","date":"February 12, 2025","format":false,"excerpt":"Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. Financial Results: Granules India Ltd reported Revenues for Q3FY25 of \u20b91,138.00 Crores down from \u20b91,156.00 Crore year on year, a fall of 1.56%. Total\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/Y-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/Y-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/Y-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/Y-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/Y-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/Y-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166149,"url":"https:\/\/alphastreet.com\/india\/granules-india-ltd-q2fy25-5-fall-in-profits\/","url_meta":{"origin":172455,"position":4},"title":"Granules India Ltd Q2FY25; 5% fall in Profits","author":"Divyansh_Kasana","date":"December 24, 2024","format":false,"excerpt":"Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. Financial Results: Granules India Ltd reported Revenues for Q2FY25 of \u20b9967.00 Crores down from \u20b91,189.00 Crore year on year, a fall of 18.67%. Total\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/GRANULES.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/GRANULES.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/GRANULES.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/GRANULES.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/GRANULES.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/GRANULES.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":151979,"url":"https:\/\/alphastreet.com\/india\/granules-india-ltd-q1fy24-62-fall-in-profits\/","url_meta":{"origin":172455,"position":5},"title":"Granules India Ltd Q1FY24; 62% fall in Profits","author":"Hardik Bhandare","date":"August 9, 2023","format":false,"excerpt":"Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. Financial Results: Granules India Ltd reported Revenues for Q1FY24 of \u20b9986.00 Crores down from \u20b91,020.00 Crore year on year, a fall of 3.33%. Total\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-436.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-436.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-436.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-436.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-436.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-436.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172455"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/172456"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}